prikaz prve stranice dokumenta Pseudomonas aeruginosa antimicrobial susceptibility profiles, resistance mechanisms and international clonal lineages: update from ESGARS-ESCMID/ISARPAE Group
  Download
PDF 1.04 MB
Scientific paper - Original scientific paper
Pseudomonas aeruginosa antimicrobial susceptibility profiles, resistance mechanisms and international clonal lineages: update from ESGARS-ESCMID/ISARPAE Group
Clinical Microbiology and Infection, 30 (2024), 4; 480. https://doi.org/10.1016/j.cmi.2023.12.026
Oliver, Antonio; Rojo-Molinero, Estrella; Arca-Suarez, Jorge; Beşli, Yeşim; Bogaerts, Pierre; Cantón, Rafael; Cimen, Cansu; Croughs, Peter D.; Denis, Olivier; Giske, Christian G.; Graells, Tíscar; Daniel Huang, Te-Din; Iorga, Bogdan I.; Karatuna, Onur; Kocsis, Béla; Kronenberg, Andreas; López-Causapé, Carla; Malhotra-Kumar, Surbhi; Martínez, Luis Martínez; Mazzariol, Annarita; Meyer, Sylvain; Naas, Thierry; Notermans, Daan W.; Oteo-Iglesias, Jesús; Pedersen, Torunn; Pirš, Mateja; Poeta, Patricia; Poirel, Laurent; Pournaras, Spyros; Sundsfjord, Arnfinn; Szabó, Dora; Tambić-Andrašević, Arjana; Vatcheva-Dobrevska, Rossitza; Vitkauskienė, Astra; Jeannot, Katy More authors...

Cite this document

Oliver, A., Rojo Molinero, E., Arca Suarez, J., Beşli, Y., Bogaerts, P., Cantón, R. ... Jeannot, K. (2024). Pseudomonas aeruginosa antimicrobial susceptibility profiles, resistance mechanisms and international clonal lineages: update from ESGARS-ESCMID/ISARPAE Group. Clinical Microbiology and Infection, 30. (4), 469. doi: 10.1016/j.cmi.2023.12.026

Oliver, Antonio, et al. "Pseudomonas aeruginosa antimicrobial susceptibility profiles, resistance mechanisms and international clonal lineages: update from ESGARS-ESCMID/ISARPAE Group." Clinical Microbiology and Infection, vol. 30, no. 4, 2024, pp. 469. https://doi.org/10.1016/j.cmi.2023.12.026

Oliver, Antonio, Estrella Rojo Molinero, Jorge Arca Suarez, Yeşim Beşli, Pierre Bogaerts, Rafael Cantón, Cansu Cimen, et al. "Pseudomonas aeruginosa antimicrobial susceptibility profiles, resistance mechanisms and international clonal lineages: update from ESGARS-ESCMID/ISARPAE Group." Clinical Microbiology and Infection 30, no. 4 (2024): 469. https://doi.org/10.1016/j.cmi.2023.12.026

Oliver, A., et al. (2024) 'Pseudomonas aeruginosa antimicrobial susceptibility profiles, resistance mechanisms and international clonal lineages: update from ESGARS-ESCMID/ISARPAE Group', Clinical Microbiology and Infection, 30(4), pp. 469. doi: 10.1016/j.cmi.2023.12.026

Oliver A, Rojo Molinero E, Arca Suarez J, Beşli Y, Bogaerts P, Cantón R, and sur.. Pseudomonas aeruginosa antimicrobial susceptibility profiles, resistance mechanisms and international clonal lineages: update from ESGARS-ESCMID/ISARPAE Group. Clinical Microbiology and Infection [Internet]. 2024 April [cited 2024 December 05];30(4):469. doi: 10.1016/j.cmi.2023.12.026

A. Oliver, et al., "Pseudomonas aeruginosa antimicrobial susceptibility profiles, resistance mechanisms and international clonal lineages: update from ESGARS-ESCMID/ISARPAE Group", Clinical Microbiology and Infection, vol. 30, no. 4, pp. 469, April 2024. [Online]. Available at: https://urn.nsk.hr/urn:nbn:hr:127:735057. [Accessed: 05 December 2024]

Please login to the repository to save this object to your list.
Metadata
Title (english)Pseudomonas aeruginosa antimicrobial susceptibility profiles, resistance mechanisms and international clonal lineages: update from ESGARS-ESCMID/ISARPAE Group
AuthorAntonio Oliver
AuthorEstrella Rojo-Molinero
AuthorJorge Arca-Suarez
AuthorYeşim Beşli
AuthorPierre Bogaerts
AuthorRafael Cantón
AuthorCansu Cimen
AuthorPeter D. Croughs
AuthorOlivier Denis
AuthorChristian G. Giske
AuthorTíscar Graells
AuthorTe-Din Daniel Huang
AuthorBogdan I. Iorga
AuthorOnur Karatuna
AuthorBéla Kocsis
AuthorAndreas Kronenberg
AuthorCarla López-Causapé
AuthorSurbhi Malhotra-Kumar
AuthorLuis Martínez Martínez
AuthorAnnarita Mazzariol
AuthorSylvain Meyer
AuthorThierry Naas
AuthorDaan W. Notermans
AuthorJesús Oteo-Iglesias
AuthorTorunn Pedersen
AuthorMateja Pirš
AuthorPatricia Poeta
AuthorLaurent Poirel
AuthorSpyros Pournaras
AuthorArnfinn Sundsfjord
AuthorDora Szabó
AuthorArjana Tambić-Andrašević
AuthorRossitza Vatcheva-Dobrevska
AuthorAstra Vitkauskienė
AuthorKaty Jeannot
Author's institution(University hospital for infectious diseases "Dr. Fran Mihaljević")
Author's institutionUniversity of Zagreb
School of Dental Medicine
Scientific / art field,
discipline and subdiscipline		BIOMEDICINE AND HEALTHCARE
Clinical Medical Sciences
Abstract (english)
Scope: Pseudomonas aeruginosa, a ubiquitous opportunistic pathogen considered one of the paradigms of antimicrobial resistance, is among the main causes of hospital -acquired and chronic infections associated with significant morbidity and mortality. This growing threat results from the extraordinary capacity of P. aeruginosa to develop antimicrobial resistance through chromosomal mutations, the increasing prevalence of transferable resistance determinants (such as the carbapenemases and the extendedspectrum fi-lactamases), and the global expansion of epidemic lineages. The general objective of this initiative is to provide a comprehensive update of P. aeruginosa resistance mechanisms, especially for the extensively drug -resistant (XDR)/difficult-to-treat resistance (DTR) international high -risk epidemic lineages, and how the recently approved fi-lactams and fi-lactam/fi-lactamase inhibitor combinations may affect resistance mechanisms and the definition of susceptibility profiles. Methods: To address this challenge, the European Study Group for Antimicrobial Resistance Surveillance (ESGARS) from the European Society of Clinical Microbiology and Infectious Diseases launched the 'Improving Surveillance of Antibiotic -Resistant Pseudomonas aeruginosa in Europe (ISARPAE)' initiative in 2022, supported by the Joint programming initiative on antimicrobial resistance network call and included a panel of over 40 researchers from 18 European Countries. Thus, a ESGARS-ISARPAE position paper was designed and the final version agreed after four rounds of revision and discussion by all panel members. Questions addressed in the position paper: To provide an update on (a) the emerging resistance mechanisms to classical and novel anti-pseudomonal agents, with a particular focus on fi-lactams, (b) the susceptibility profiles associated with the most relevant fi-lactam resistance mechanisms, (c) the impact of the novel agents and resistance mechanisms on the definitions of resistance profiles, and (d) the globally expanding XDR/DTR high -risk lineages and their association with transferable resistance mechanisms. Implication: The evidence presented herein can be used for coordinated epidemiological surveillance and decision making at the European and global level. Antonio Oliver, Clin Microbiol Infect 2024;30:469 (c) 2023 The Authors. Published by Elsevier Ltd on behalf of European Society of Clinical Microbiology and Infectious Diseases. This is an open access article under the CC BY -NC -ND license (http:// creativecommons.org/licenses/by-nc-nd/4.0/).
Keywords (english)
Languageenglish
Publication typeScientific paper - Original scientific paper
Publication statusPublished
Peer reviewPeer review - international
Publication versionPublished version
Journal titleClinical Microbiology and Infection
Numberingvol. 30, no. 4, p. 469, 480
p-ISSN1198-743X
DOIhttps://doi.org/10.1016/j.cmi.2023.12.026
URN:NBNurn:nbn:hr:127:735057
Publication2024-04
Document URLhttps://linkinghub.elsevier.com/retrieve/pii/S1198743X23006341
Type of resourceText
Access conditionsOpen access
Terms of useLicence Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0) icon
Created on2024-06-28 09:07:59